Melanotan II for Sexual Enhancement: Known Risks
Melanotan II and Sexual Function
17 of 20
In a placebo-controlled trial, melanotan II induced penile erections in 17 of 20 men with erectile dysfunction, without any sexual stimulation.
Wessells et al., Int J Impotence Research, 2000
Wessells et al., Int J Impotence Research, 2000
View as imageMelanotan II was never designed as a sexual enhancement drug. Researchers at the University of Arizona developed it in the 1990s as a synthetic analogue of alpha-melanocyte-stimulating hormone to induce tanning without UV exposure. But in the first Phase I trial, something unexpected happened: participants developed spontaneous penile erections lasting 1 to 5 hours after subcutaneous injection.[1] That finding launched melanotan II's second life as an underground sexual enhancement peptide, purchased online and self-injected by thousands of users with no medical oversight, no standardized dosing, and no quality controls on what they are injecting.
The pro-erectile effects are real and documented in controlled trials. But the risk profile extends well beyond nausea and flushing. Published case reports describe rhabdomyolysis with creatine kinase levels exceeding 17,000 IU/L, renal infarction, and melanoma in situ.[3][5][4] And unlike bremelanotide (PT-141), which was derived from melanotan II and went through full FDA clinical trials, melanotan II itself has never completed regulatory approval for any indication.
Key Takeaways
- Melanotan II induced penile erections in 17 of 20 men with erectile dysfunction in a placebo-controlled trial, with 68% reporting increased desire versus 19% on placebo (Wessells et al., 2000)
- A 39-year-old man who injected 6 mg of melanotan II (6x the recommended dose) developed rhabdomyolysis with creatine kinase peaking at 17,773 IU/L, requiring ICU admission (Nelson et al., 2012)
- Melanotan II use has been linked to renal infarction through possible thrombotic mechanisms and direct renal toxicity (Peters et al., 2020)
- A 22-year-old woman developed oral mucosal malignant melanoma after using melanotan II nasal spray for tanning (Yassin et al., 2025)
- Bremelanotide, derived from melanotan II, showed 40% nausea rates and transient blood pressure increases across 3,500 clinical trial subjects (Clayton et al., 2022)
- Melanotan II remains unapproved by the FDA, EMA, and TGA, with no standardized manufacturing, dosing, or purity testing for products sold online
How Melanotan II Produces Sexual Effects
Melanotan II is a non-selective melanocortin receptor agonist. It binds to MC1R (skin pigmentation), MC3R (energy homeostasis), MC4R (appetite and sexual function), and MC5R (exocrine gland function). The sexual effects arise primarily from MC3R and MC4R activation in the hypothalamus and limbic system.[9]
Pfaus et al. (2007) demonstrated that melanocortin receptor agonists activate the medial preoptic area of the brain, a region critical for both male erectile function and female sexual motivation. In female rats, bremelanotide (melanotan II's derivative) dramatically increased solicitation behaviors after direct infusion into this brain region, likely by activating dopamine terminals.[9]
The mechanism is distinct from phosphodiesterase-5 inhibitors like sildenafil (Viagra), which work peripherally on blood vessels. Melanotan II acts centrally, on brain circuits that control sexual desire and arousal, which is why it produces spontaneous erections even without sexual stimulation and increases subjective desire.[2] This central mechanism is also why it produces a wide range of neurological side effects, including nausea, yawning, stretching, and somnolence, that peripheral erectile drugs do not cause.
The Clinical Trial Evidence
Only a handful of controlled studies have tested melanotan II in humans, all with small sample sizes.
Dorr et al. (1996) conducted the first Phase I study in three normal male volunteers. Subcutaneous injections at doses from 0.01 to 0.03 mg/kg produced a characteristic yawning-stretching complex followed by spontaneous erections lasting 1 to 5 hours. Two of three subjects developed measurable skin darkening after just five doses. The 0.03 mg/kg dose produced Grade II somnolence and fatigue. Nausea occurred at most dose levels. The recommended starting dose was set at 0.025 mg/kg.[1]
Wessells et al. (2000) expanded this to a double-blind, placebo-controlled crossover trial in 20 men with both psychogenic and organic erectile dysfunction. Melanotan II at 0.025 mg/kg produced penile erections (defined as >80% tip rigidity on RigiScan) in 17 of 20 men, with an average of 41 minutes of full rigidity. Increased sexual desire was reported after 68% of active doses versus 19% of placebo doses (P<0.01). At this dose, 12.9% of subjects experienced severe nausea.[2]
These results were striking enough to spawn the development of bremelanotide (PT-141), a metabolite of melanotan II that Palatin Technologies advanced through full clinical trials for hypoactive sexual desire disorder rather than erectile dysfunction.[7]
Why Melanotan II Was Never Approved
Despite the pro-erectile data, melanotan II was never developed as a drug. The reasons are pharmacological:
Non-selectivity. Melanotan II hits all five melanocortin receptors. This means every injection produces tanning (MC1R), appetite changes (MC3R/MC4R), sexual effects (MC3R/MC4R), and systemic effects that are difficult to separate. A drug that does everything is a drug that cannot be dosed for one thing.[7]
Blood pressure elevation. Melanocortin receptor activation raises blood pressure through sympathetic nervous system stimulation. Even bremelanotide, after full clinical development, carries a warning about transient blood pressure increases observed during ambulatory monitoring. The FDA recommends caution in patients at cardiovascular risk.[8]
Uncontrollable tanning. Melanotan II was originally designed to tan, and it does. But the pigmentation is unpredictable, non-uniform, and includes darkening of moles and nevi, which complicates skin cancer screening. Any drug that makes melanoma harder to detect is not going to clear regulatory review easily.[4]
Bremelanotide solved some of these problems by being more selective for MC4R over MC1R, meaning less tanning. It was approved by the FDA in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder, as a subcutaneous on-demand injection.[7] This represents the legitimate clinical pathway that melanotan II never completed.
Documented Serious Adverse Events
The case report literature on melanotan II contains several alarming entries that go beyond the nausea and flushing seen in controlled trials.
Rhabdomyolysis and Renal Failure
Nelson et al. (2012) reported a 39-year-old man who self-injected 6 mg of melanotan II purchased online, approximately six times the recommended starting dose. Two hours post-injection, he presented with diffuse body aches, sweating, anxiety, tachycardia (130 bpm, peaking at 146), mydriasis, diaphoresis, and diffuse muscle tremors. His creatinine was 2.25 mg/dL and creatine kinase (CPK) was 1,760 IU/L at presentation, rising to 17,773 IU/L within 12 hours. He required ICU admission with intravenous fluids and sodium bicarbonate for rhabdomyolysis. Mass spectrometry confirmed the injected substance was melanotan II.[3]
This case demonstrated a sympathomimetic toxidrome: hypertension, tachycardia, mydriasis, and agitation, suggesting melanotan II can trigger massive sympathetic nervous system activation at supratherapeutic doses.
Renal Infarction
Peters et al. (2020) reported a case of renal infarction most likely attributed to melanotan II use. They reviewed the literature on melanotan II's renal effects and identified two possible mechanisms: a thrombotic pharmacological influence (melanotan II may promote clot formation) and a direct toxic effect on renal parenchyma. Previous reports of rhabdomyolysis-induced renal failure support the second mechanism. The authors noted that renal infarction is an uncommon, potentially life-threatening condition that is frequently misdiagnosed.[5]
Melanoma
Ong and Bowling (2012) reported a case of melanotan-associated melanoma in situ in a young woman using injectable melanotan for tanning. They noted prior reports of dysplastic nevi associated with melanotropic peptide use and emphasized that melanotan products are unlicensed compounds with an unproven safety record.[4]
More recently, Yassin et al. (2025) reported a 22-year-old woman who developed oral mucosal malignant melanoma after using melanotan II as a nasal spray for tanning. Histological analysis confirmed the diagnosis, and she required surgical resection followed by immunotherapy. Whether melanotan II directly caused the melanoma or accelerated an existing process is unclear, but the case adds to a pattern of melanocytic neoplasia associated with melanotropic peptide exposure.[6]
What Bremelanotide Safety Data Reveals About Melanocortin Risk
Because melanotan II never completed a full clinical program, the best systematic safety data for melanocortin agonist sexual effects comes from bremelanotide trials.
Clayton et al. (2022) reviewed bremelanotide's safety across the entire clinical development program, comprising 3,500 subjects in 43 completed studies. In the Phase 3 double-blind portions (N=1,247), the most common adverse events with bremelanotide versus placebo were nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%), and injection site reactions (5.4% vs 0.5%). Nausea was the most common reason for discontinuation.[8]
Small, transient blood pressure increases were statistically significant during ambulatory monitoring. Focal hyperpigmentation was rare at recommended dosing but occurred in more than one-third of subjects who received up to 16 consecutive daily doses. Drug interactions were mostly non-significant, except for reduced plasma concentrations of indomethacin and naltrexone.[8]
These are the side effects of a refined, single-receptor-optimized derivative given at controlled doses under medical supervision. Melanotan II is less selective, sold in unverified concentrations, and used without monitoring. The risks are predictably worse.
The Unregulated Supply Problem
Melanotan II is not approved by the FDA, EMA, TGA, or any major regulatory body for any indication. Products sold online as "research chemicals" are manufactured without pharmaceutical-grade quality controls. Users have no assurance that the vial contains melanotan II at the stated concentration, that it is free of contaminants, or that it has been stored properly.
The difference between melanotan I and melanotan II adds further confusion: melanotan I (afamelanotide) is a linear alpha-MSH analogue that is FDA-approved as Scenesse for erythropoietic protoporphyria, while melanotan II is a cyclic non-selective agonist with no approvals. Online vendors sometimes conflate the two.
The Nelson (2012) rhabdomyolysis case is instructive: the patient injected 6 mg, six times the recommended starting dose described in the Dorr Phase I trial. Without medical guidance, users default to community-sourced dosing protocols from bodybuilding and tanning forums where escalation is common and the distinction between 0.025 mg/kg (the studied dose) and a flat 1-2 mg dose (common online recommendation) is rarely addressed.
For erectile dysfunction specifically, bremelanotide (Vyleesi) represents the evidence-based melanocortin option, though it is currently approved only for female HSDD, not male erectile dysfunction. Research on PT-141 for male ED continues, but off-label melanotan II use carries risks that controlled pharmaceutical alternatives do not.
The dosing problem compounds the purity problem. Clinical studies used weight-based dosing (0.025 mg/kg) delivered subcutaneously, with careful titration and monitoring. Online protocols typically recommend flat doses of 0.5 to 2 mg regardless of body weight, with some users escalating rapidly when initial doses produce more nausea than effect. The Nelson rhabdomyolysis case involved a dose six times higher than the studied maximum. Without medical supervision, the margin between a dose that produces erections and a dose that produces organ damage is unknown for any individual user. This is not a compound that failed safety testing. It is a compound that never completed safety testing, and the distinction matters.
The Bottom Line
Melanotan II produces genuine pro-erectile and pro-desire effects through central melanocortin receptor activation, documented in small controlled trials showing erections in 85% of ED patients and increased desire at rates 3.5 times higher than placebo. But the compound was never developed as a drug because of its non-selective receptor binding, unpredictable tanning, and cardiovascular effects. Published case reports document rhabdomyolysis, renal infarction, and melanoma in users of unregulated online products. Bremelanotide, the FDA-approved derivative, demonstrates that melanocortin agonism can be made safer through receptor selectivity, controlled dosing, and clinical monitoring, but melanotan II itself provides none of these safeguards.